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DOI 10.1186/s12943-015-0482-2RESEARCH Open AccessInsulin-like growth factors are essential to
prevent anoikis in oestrogen-responsive
breast cancer cells: importance of the type
I IGF receptor and PI3-kinase/Akt pathway
Brendan C. Luey and Felicity E. B. May*Abstract
Background: Detachment of epithelial cells from the extracellular matrix initiates programmed cell death by a process
termed anoikis. Malignant cells must acquire anoikis resistance to leave the primary tumour and metastasise. Multiple
signal transduction pathways can activate anoikis and confer anoikis resistance, but these are not understood in breast
cancer.
Methods: Models for anoikis of oestrogen-responsive breast cancer cells were established and the protective effects of
IGF-1 tested. Cleaved PARP was measured by western transfer and cleaved caspase 3 by flow cytometry. Pathways
involved in anoikis and in anoikis resistance were investigated with PI3-kinase, Akt, and MEK1 and MEK2 inhibitors. The
importance of the type I IGF receptor was investigated by IGF-concentration dependence, siRNA knockdown and
pharmacological inhibition. Association between IGF-1R expression and relapse with distant metastasis was analysed in
1609 patients by log rank test.
Results: Unattached breast cancer cells required culture in serum-free medium to induce anoikis. Rapid loss of FAK, Akt
and Bad phosphorylation was concurrent with anoiks induction, but ERK1 and ERK2 phosphorylation increased which
suggested that anoikis resistance is mediated by the PI3-kinase/Akt rather than the Grb2/Ras/MAP-kinase pathway. IGF-1
conferred anoikis resistance in serum-free medium. IGF-1 activated the PI3-kinase/Akt and Grb2/Ras/MAP-kinase pathways
but experiments with PI3-kinase, Akt and MEK1 and MEK2 inhibitors showed that IGF protection is via the PI3-kinase/Akt
pathway. The concentration dependence of IGF protection, knockdown experiments with siRNA and pharmacological
inhibition with figitumumab, showed that IGF-1 signals through the type I IGF receptor. The crucial role of the type I IGF
receptor was demonstrated by induction of anoikis in full serum by figitumumab. High IGF-1R expression was associated
with reduced time to relapse with distant metastases in oestrogen receptor-positive patients, especially those with
aggressive disease which confirms its relevance in vivo.
Conclusions: Anoikis resistance of oestrogen-responsive breast cancer cells depends upon IGF activation of the type I IGF
receptor and PI3-kinase/Akt pathway. Because IGF-dependent evasion of anoikis will facilitate metastasis by malignant
breast cancer cells, effective inhibition of IGF signal transduction should be included in combinations of targeted drugs
designed to treat metastatic oestrogen receptor-positive breast cancers.
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Worldwide, more than 1.7 million women are diagnosed
annually with breast cancer of whom at least 500,000 die as
a result of metastatic disease [1]. Metastasis necessitates re-
lease of malignant cells from the primary tumour and their
movement to and establishment at distant sites. Normal
breast epithelial and myoepithelial cells attach to each other
and to the extracellular matrix. Loss of these attachments
induces programmed cell death in a process called anoikis
[2–4]. Breast cancer cells must become resistant to anoikis
as they invade breast and surrounding tissue, intravasate
into blood and lymphatic vessels and metastasise [5]. Block-
ade of the pathways responsible for anoikis resistance offers
a powerful strategy for the elimination of metastatic cells.
Integrins are transmembrane proteins that provide con-
nections between extracellular matrix proteins and the
actin-based cytoskeleton in normal tissues. Integrins trans-
duce signals via sub-membrane, focal adhesion protein
complexes, called focal adhesions, which connect integrins
with signal transduction proteins [6, 7]. Integrin engage-
ment activates focal adhesion kinase (FAK) to suppress
anoikis [3] by transmission of cell survival signals through
multiple signal transduction pathways [3, 8].
The effects of insulin-like growth factors (IGFs) are medi-
ated by the transmembrane type I IGF or insulin receptors
and multiple intracellular signal transduction pathways [9].
Work with transgenic animals implicates IGFs in carcino-
genesis [10] and they are significant regulators of breast
cancer cell proliferation and invasion [11–15]. Conse-
quently, the IGF signal transduction pathway has been
identified as a therapeutic target and inhibitors of the type I
IGF receptor have been developed by pharmaceutical
companies [9, 16–21].
IGFs confer anoikis resistance in embryonic fibroblasts
that have been engineered to overexpress the type I IGF
receptor [22] but the importance of IGFs in anoikis
resistance and the mechanism by which they might
act in oestrogen-responsive breast cancer is unknown.
Similarly, the signal transduction pathways involved in
the induction of anoikis and in anoikis resistance of
breast cancer cells have not been determined.
There have been a few studies that purport to examine
the effects of the IGF signal transduction pathway upon
anoikis breast cancer cells. However, caspase-dependent
programmed cell death was not measured in these studies.
In immortalized, normal MCF710A cells that have been
modified to overexpress the type I IGF receptor, PTK6 in-
creased signal transduction through the type I IGF recep-
tor and IRS-1 increased the number of viable cells grown
in unattached conditions [23]. Another study reported
that effects of IGF on the ratio of isoforms of the C/EBPβ
protein reduced the proportion of unattached MCF710A
cells in sub-G1 phase [24]. Disruption of the type I IGF
receptor signal transduction pathway decreased numbersof viable cells of a metastatic variant of MDA-MB-435
breast cancer cell line grown as unattached cells [14]. An-
other study reported that activation of the p53 pathway
after MCF-7 cell detachment leads to a caspase-
independent reduction in mitochondrial activity, and that
calveolin may reverse the reduction via an increase in type
I IGF receptor [25]. Thus, despite the impression con-
veyed in the titles or abstracts of these articles, there have
been no studies of the effects of IGFs on anoikis in human
breast cancer cells.
We have shown that IGFs inhibit apoptosis in triple-
negative breast cancer cells [12] which suggested that they
could protect against breast cancer cell anoikis and that
blockade of the IGF signal transduction pathway might
offer a strategy for promoting anoikis and reducing
metastasis. The overall aim of the current study was to
investigate the mechanisms by which oestrogen-responsive
breast cancer cells evade anoikis. We established an
in vitro model of anchorage-independent, caspase-
dependent cell death and investigated the changes in
intracellular signal transduction involved, whether IGF-
1 protects the cells from anoikis and the receptor and
signal transduction pathway through which IGFs act.
Results
Model of anoikis in oestrogen-responsive breast cancer
MCF-7 cells were added to uncoated or poly-HEMA-
coated culture wells to prevent cell attachment [26]. After
24 h, cells in the poly-HEMA-coated wells grew as
rounded cells in suspension (Fig. 1). To investigate if the
unattached MCF-7 cells had undergone programmed cell
death via the caspase-dependent pathway, we measured
the cleavage of PARP into the 89 kDa catalytic and 24 kDa
DNA binding subunits which cannot repair single-strand
DNA breaks. No cleaved PARP was detected in attached
or unattached cells cultured in maintenance medium.
Attached cells grown in serum-free medium for 24 h
maintained their characteristic polygonal morphology and
PARP cleavage was not detected. PARP cleavage was
induced, however, in unattached cells after 24 h in serum-
free medium. Culture of attached cells in serum-free
medium for up to three days did not induce significant cell
death (data not shown).
Oestrogen-responsive breast cancer cells, ZR-75 and
EFM-19, also lost their characteristic epithelial appear-
ance and grew as rounded cells after 24 h culture in
poly-HEMA-coated wells in serum-free medium
(Fig. 1A-C). A small amount of cleaved PARP was de-
tected in unattached ZR-75 after 5 h and substantially
more after 24 h. Cleaved PARP was detected readily in
unattached EFM-19 at 1 h and was almost maximal
after 6 h. Anoikis was induced also in T-47D cells after
24 h (data not shown). PARP cleavage was not detected
in attached cells grown in serum-free medium.
Fig. 1 Caspase-dependent programmed cell death of unattached oestrogen-responsive breast cancer cells. MCF-7, ZR-75 and EFM-19 cells were
cultured in maintenance medium, trypsinised and added to uncoated or poly-HEMA-coated 35-mm-diameter wells in maintenance medium (10 % serum)
or serum-free medium (Serum free) and cultured for 24 h (a). Cells were lysed after the indicated times and 10 μg protein aliquots were electrophoresed
on 12 % polyacrylamide gels, transferred to nitrocellulose and the amount of 89 kDa cleaved PARP and GAPDH measured by western transfer analysis.
Representative western transfer images are shown (b). The amount of each protein was determined by densitometric scanning of X-ray films. The amount
of cleaved PARP was corrected for GAPDH expression with Labworks 4 software and is expressed as the percentage of the maximum value measured for
each cell line (c). The mean values ± SEM are shown. Asterisks show times at which there is statistically significantly more cleaved PARP in the unattached
cells than in attached cells (ANOVA, p < 0.01). EFM19 cells were incubated in serum-free medium in poly-HEMA-coated 22-mm-diameter wells, fixed,
permeabilised and incubated with FITC-conjugated antibody against activated caspase 3 and analysed in a FACSCalibur as described in the Materials
and Methods. Representative histograms are shown (d). Each experiment included triplicate samples and was replicated thrice
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caspase-dependent programmed cell death. It is activated
by cleavage into 17 kDa and 12 kDa subunits; the pres-
ence of which indicate that cells are in the execution
stages of programmed cell death. Activated caspase 3 was
detected by flow cytometry in less than 1 % of the cells
prior to and in 15 % of the cells after induction of anoikis
(Fig. 1D; student t-test; p < 0.01) which confirmed that
caspase-dependent anoikis had been induced.
Effect of loss of attachment on signal transduction
To investigate alterations in signal transduction that could
account for the anoikic response, EFM-19 cells were grown
attached or unattached in serum-free medium for differentlengths of time. PARP cleavage was detected after 1 h in
the unattached cells and increased thereafter for 24 h
(Fig. 2). Little PARP cleavage was detected in attached cells
even after 24 h.
The phosphorylation of proteins implicated in anoikis
was then measured. There was a dramatic decrease in FAK
phosphorylation within 15 min of prevention of cell attach-
ment whereas there was no reduction in FAK phosphoryl-
ation in attached cells cultured in serum-free medium for
the same length of time. The levels of phosphorylated FAK
were minimal by 1 h and decreased further up to 24 h
concurrent with the increase in PARP cleavage. There was
no concomitant change in the levels of FAK protein. FAK
phosphorylation was reduced also in unattached MCF-7
Fig. 2 Effect of loss of attachment on activation of signal transduction proteins in breast cancer cells. EFM-19 cells (a, b and c), MCF-7 (c) and
ZR-75 cells (c) were trypsinised, added to 35-mm-diameter cell culture wells that had not (uncoated) or had been coated with poly-HEMA and cultured
for the indicated lengths of time in serum-free medium. Cells were lysed and aliquots of 10 μg of protein were electrophoresed on 12 % polyacrylamide
gels, transferred to nitrocellulose and the amounts of cleaved PARP, phosphorylated FAK, Akt, Bad, ERK1 and ERK2 and the corresponding total proteins
and GAPDH were measured as described in the Materials and Methods. Representative images of the results obtained are shown (a and c) with the
images for each phosphorylated protein above those of the equivalent total protein (c). The amounts of cleaved PARP and phosphorylated FAK were
determined by densitometric scanning of X-ray films followed by analysis with Labworks 4 software and correction for GAPDH. The results obtained are
expressed as a percentage of the maximum amount of cleaved PARP protein measured or phosphorylated FAK measured in attached (o) or unattached
(•) cells. The bars show the standard errors of the mean. Asterisks show cleaved PARP that is statistically significantly more, or phosphorylated FAK that is
statistically significantly less, in unattached cells than in attached cells (ANOVA, p < 0.01)
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Fig. 3 Protective effect of IGF-1 against anchorage-dependent
programmed cell death in breast cancer cells. MCF-7 (a and b),
ZR-75 cells (a and b), and EFM-19 cells (a, b and c) were trypsinised,
resuspended in serum-free medium alone or with 50 ng/ml IGF-1,
placed in 35-mm-diameter poly-HEMA-coated wells and cultured for
the indicated lengths of time. Cells were lysed and aliquots of
protein analysed by western transfer for cleaved PARP and GAPDH.
Representative western transfer images are shown (a). The amount
of each protein was determined by densitometric scanning of X-ray
films, corrected for GAPDH and is expressed as the percentage of
the maximum value for each cell line (b). Asterisks show times at
which cleaved PARP is statistically significantly less, in the presence
of IGF-1 than in its absence (ANOVA, p < 0.001). EFM-19 cells were
collected, fixed, permeabilised and incubated with FITC-conjugated
antibody against activated caspase 3 and analysed in a FACSCalibur.
Representative histograms are shown (c). The data was analysed with
WinMDI which confirmed the protective effect of IGF-1 (p = 0.003)
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serum free medium for 24 h. Consistent with a role
of the PI3-kinase/Akt pathway in anoikis, Akt phos-
phorylation was reduced dramatically in MCF-7 and
to a lesser extent in ZR-75 and EFM-19. The reduc-
tion of Akt phosphorylation led to a reduction in
phosphorylation of its downstream target, Bad, in
MCF-7 and EFM-19. Reduced phosphorylation of Bad
promotes cell death because unphosphorylated Bad se-
questers anti-apoptotic Bcl family proteins which prevents
their inhibition of pro-apoptotic proteins Bax and Bak.
In contrast to Akt phosphorylation, phosphorylation
of ERK1 and ERK2 was increased slightly in MCF-7
and markedly in EFM-19 and ZR-75 cells induced to
undergo anoikis which suggests that the Grb2/Ras/
MAP-kinase pathway has not been dampened and
that it is unlikely to transduce the integrin-dependent
cell survival signal. The results are consistent with
oestrogen-responsive breast cancer cell attachment ac-
tivating FAK to signal through the PI3-kinase/Akt/Bad
pathway to provide an important cell survival signal in
attached oestrogen-responsive breast cancer cells.
IGFs protect oestrogen-responsive breast cancer cells from
anoikis
Many factors in serum might account for the anoikis re-
sistance of oestrogen-responsive breast cancer cells. To
test if IGFs in serum might contribute to the anoikis re-
sistance of unattached oestrogen-responsive breast can-
cer cells cultured in maintenance medium, cells were
cultured in poly(HEMA)-coated wells in serum-free
medium in the absence or presence of IGF-1 (Fig. 3).
The amount of cleaved PARP detected was lower in cells
cultured in the presence of IGF-1 than in its absence
(p < 0.001). IGF-1 prevented completely the induction of
anoikis in MCF-7, inhibited it thirty-fold in ZR-75 and
ten-fold in EFM-19 cells.
The protective effect of IGF-1 on the induction of anoikis
was analysed also by measuring activated caspase 3. The pro-
portion of EFM-19 cells with activated caspase 3 in the execu-
tion phase of cell death was reduced by 78 % in cells cultured
in poly-HEMA-coated dishes in the presence of IGF-1 com-
pared to in cells cultured in its absence (Fig. 3C; p < 0.01),
which confirms that IGF-1 protects cells from caspase-
dependent anoikis and suggests that they might be important
contributors to the resistance conveyed by culture in serum.
The downstream signal transduction pathways that
might be responsible for the protective effect of IGF-1 in
oestrogen-responsive breast cancer cells were investigated.
IGF-1 stimulated auto-phosphorylation of IGF receptors
in all three cell lines (Fig. 4). Activated IGF receptors
interact with and induce phosphorylation of adaptor pro-
teins of which IRS-1 is considered to be the most import-
ant for signalling via both PI3-kinase/Akt and Grb2/Ras/MAP-kinase pathways [27]. IRS-1 phosphorylation was in-
duced by nanomolar concentrations of IGF-1. Phosphoryl-
ation of Akt was stimulated by 2 ng/ml IGF-1 in MCF-7
and ZR-75 and by 20 ng/ml IGF-1 in EFM-19, and of Bad
by 0.5 ng/ml IGF-1 in MCF-7 and ZR-75 and by 20 ng/ml
IGF-1 in EFM-19. Activation by phosphorylation of ERK1
Fig. 4 Activation of signal transduction proteins by IGF-1 in oestrogen-responsive breast cancer cells. MCF-7, ZR-75 and EFM-19 cells were
cultured for two days in phenol red-free medium supplemented with charcoal-treated serum, for 2 h in serum-free medium and incubated in the
absence or presence of the indicated concentrations of IGF-1 for 15 min in the same medium. Aliquots of 10 μg of protein were electrophoresed
on polyacrylamide gels, transferred to nitrocellulose and incubated with antibodies specific for phosphorylated IGF receptor, phosphorylated IRS-1,
phosphorylated Akt, phosphorylated Bad, and phosphorylated ERK1 and ERK2, antibodies against the equivalent total proteins and developed as
described in the Materials and Methods. Representative images from the phosphorylated protein are shown above those of the equivalent total protein
Luey and May Molecular Cancer  (2016) 15:8 Page 6 of 15and ERK2 was stimulated most markedly in ZR-75 cells
but required higher IGF-1 concentrations, 20 ng/ml, than
for the stimulation of Akt phosphorylation. The total
levels of the signal transduction proteins did not change
during the IGF-1 treatment.
These experiments show that oestrogen-responsive
cells are protected from cell death by anchorage
dependent signals from integrins through FAK and Akt
(Fig. 5A). Resistance to anoikis can be mediated through
the IGF signal transduction pathway. IGFs activate the
PI3-kinase/Akt, and the Grb2/Ras/MAP-kinase signal
transduction pathways both of which have been implicated
in anoikis resistance.Signal transduction pathway that mediates the anti-anoikic
effect of IGF-1
The importance of the PI3-kinase/Akt pathway in the IGF-
dependent anoikis resistance was tested with LY294002, a
selective, reversible inhibitor of ATP binding in the cata-
lytic subunit of PI3-kinase [28, 29]. Unattached MCF-7
cells were cultured in serum-free medium in poly-HEMA-
coated wells in the absence or presence of IGF-1 and
LY294002. Neither the IGF receptors nor Akt were phos-
phorylated in untreated cells which indicates that there is
no signalling through the PI3-kinase/Akt pathway (Fig. 6).
Phosphorylation of the IGF receptors stimulated by IGF-1
was not affected by LY294002 whereas IGF-stimulated
Fig. 5 Importance of the type I IGF receptor and PI3-kinase\Akt pathway in the IGF-protection from anoikis. Representations of the alpha and beta
integrins (cyan and light purple) and their activation of Akt via the focal adhesion and FAK signal transduction pathway (green) (a). The homo-tetrameric
type I IGF receptor (IGF-IR, pink) has the α-chains of each receptor coloured lighter than the β-chains. The extracellular ligands: insulin (orange), IGF-2
(ochre) and IGF-1 (pale yellow) are shown. Signal transduction from the activated receptor is depicted through IRS-1 via the PI3-kinase, PIP3, mTOR2,
PDPK1 and Akt pathway (pink) or the Grb2, SOS, Ras, Raf, MEK1 and MEK2, ERK1 and ERK2 pathway (purple). The downward pointing grey arrow indicates
constitutive activation of ERK1 and ERK2. The downward pointing metallic blue arrows indicate that a signal has been transduced from each pathway.
The pale gold spheres represent phosphorylated moieties. The GTP on activated Ras is a light yellow sphere and the GDP on inactive Ras an ivory sphere.
Uncleaved inactive caspase 3 is shown as a small bright yellow sphere and uncleaved active PARP as a large bright yellow sphere. Cleaved active caspase
3 and cleaved inactive PARP are shown as the equivalent fragmented spheres. Downward pointing larger blue arrows indicate that cell survival and
downward pointing red arrows indicate that cell death ensues. Kinase inhibitors (brick red) that inhibit PI3-kinase, LY294002, or Akt, GSK 690693, abrogate
the protective effect of IGF on cell survival of unattached cells (b) whereas the MEK1 and MEK2 kinase inhibitor, U0126, does not (c). Inhibition of the type
I IGF receptor with the specific inhibitory antibody, figitumumab (brick red), induces anoikis in IGF-stimulated cells or in cells grown in serum (d)
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tial amounts of cleaved PARP were detected in the
untreated cells but very little in the presence of IGF-1. The
PI3-kinase inhibitor did not increase anoikis in the absence
of IGF-1 which is consistent with this pathway being inacti-
vated completely in unattached cells in serum-free medium.
The ability of IGF-1 to prevent cell death was reduced
20-fold by the PI3-kinase inhibitor (ANOVA; p < 0.01).The role of the PI3-kinase/Akt pathway in IGF-protection
of breast cancer cells from anoikis was tested further with
GSK690693 [30, 31] a specific, ATP-competitive inhibitor of
Akt. Activity of the Akt inhibitor was demonstrated by en-
hanced Akt phosphorylation in the presence of IGF-1 as has
been reported previously (data not shown). Phosphorylation
of GSK3β, a downstream target of Akt, was stimulated by
IGF-1 (Fig. 6) and GSK690693 inhibited this IGF-stimulated
Fig. 6 Effect of inhibition of the PI3-kinase/Akt pathway on the protection of breast cancer cells from anoikis by IGF-1. Cells were trypsinised, resuspended in
serum-free medium alone or with 50 ng/ml IGF-1 (A and B) or 10 ng/ml IGF-1 (c and d) and in the absence or presence of 20 μM LY294002 (a and b) or 100
nM GSK690693 (c and d) and then placed in 35-mm-diameter cell culture wells that had been coated with poly-HEMA and cultured for 24 h. Cells were lysed
and the amount of phosphorylated IGF receptors, phosphorylated Akt, phosphorylated GSK3β, type I IGF receptor, Akt, GSK3β, cleaved PARP and GAPDH
were measured by western transfer in aliquots of 10 μg of protein. Representative images are shown with the images for each phosphorylated protein above
those of the equivalent total protein (a and c). The means ± SEM from three experiments are shown. Statistical significance of differences between untreated
cells and cells treated with IGF-1 (*), or between cells treated with IGF-1 alone and in the presence of the inhibitor (**) are indicated (p < 0.05; ANOVA)
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attached cells but did inhibit the protective effect of IGF-1
which reinforced the supposition that the IGF-protective-
effect is transduced via the PI3-kinase/Akt pathway (Fig. 5B).
The contribution of the Grb2/Ras/MAP-kinase path-
way to the protection by IGF-1 of oestrogen-responsive
breast cancer cells from anoikis was tested with U0126
which is a non-competitive inhibitor of MEK1 and MEK2
[32, 33] that prevents activation of ERK1 and ERK2. Phos-
phorylated ERK1 and ERK2 were detected in cells in which
anoikis had been induced (Fig. 7) which suggests that the
Grb2/Ras/MAP-kinase pathway is not inactivated. IGF-1
stimulated receptor phosphorylation, increased ERK1 and
ERK2 phosphorylation, and protected cells from anoikis.
ERK1 and ERK2 phosphorylation was abrogated completelyin the presence of the MEK inhibitor and more cleaved
PARP was detected. To investigate if the increased cell
death induced by U0126 resulted from increased anoikis or
was independent of cell attachment, attached cells were
incubated in serum-free medium in the absence and
presence of U0126. MCF-7 cultured as attached cells in
serum-free medium for up to 24 h did not undergo apop-
tosis. Apoptosis was induced strongly in the presence of
U0126 (Fig. 7C) which indicates that cell death induced by
MEK inhibition is independent of cell attachment.
There was no phosphorylated ERK1 or ERK2 in cells in-
cubated in the absence or presence of IGF-1 in the presence
of the MEK inhibitor but there was a significant protective
effect of IGF-1 against anoikis in the presence of the MEK
inhibitor as evidenced by its ability to prevent PARP
BA
Cleaved PARP
GAPDH
89 kDa
95 kDa
44 kDa
44 kDa
42 kDa
42 kDa
95 kDa
37 kDa
- IGF
- IGF
- IGF
- IGF
+IGF
+IGF
+IGF
+IGF
- U0126 + U0126
20 20
40 40
60 60
80 80
100
120
100
300
  0   0
P
ho
sp
ho
ry
la
te
d 
E
R
K
1 
an
d 
 E
R
K
2 
(%
)
C
le
av
ed
 P
A
R
P
 (
%
)
- IGF - IGF- IGF - IGF+IGF +IGF+IGF +IGF
- U0126 - U0126+U0126 +U0126
∗ ∗
Phosphorylated IGF receptor
Phosphorylated ERK1 and ERK2
∗ ∗
NS
C
Cleaved PARP
GAPDH
89 kDa
37 kDa
- U0126 + U0126
attached cells 
Fig. 7 Effect of MAP kinase pathway inhibition on the protection by
IGF-1 of breast cancer cells from anoikis. MCF-7 cells were trypsinised,
resuspended in serum-free medium alone or serum free medium and
10 ng/ml IGF-1, and in the absence or presence of 1 μM U0126 and
then cultured for 24 h in 35-mm-diameter poly-HEMA-coated wells (a)
or as attached cells (c). Cells were lysed and the amount of cleaved
PARP, phosphorylated IGF receptors, phosphorylated ERK1 and ERK2,
type I IGF receptor, ERK1 and ERK2 and GAPDH were measured by
western transfer analysis in aliquots of 10 μg of protein. Representative
images are shown with the images for each phosphorylated protein
above those of the equivalent total protein (a). The means ± SEM from
three experiments are shown (b). Statistical significance of differences
between untreated cells and cells treated with IGF-1 (*), or between cells
treated with IGF-1 alone and in the presence of the inhibitor (**) are
indicated (p < 0.05; ANOVA)
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of IGF-1 against anoikis is not transduced via the Grb2/
Ras/MAP-kinase pathway (Fig. 5C).
Importance of the type I IGF receptor
Oestrogen-responsive breast cancer cells express relatively
more type I IGF receptor than the insulin receptor [12].
IGF-1 has a higher affinity for the former receptor [9, 34].
To investigate which receptor transmits the IGF-protective
signal against anoikis, unattached cells were cultured in the
presence of different concentrations of IGF-1 (Fig. 8A). There
was a small reduction in the amount of cleaved PARP in
MCF-7 cells after culture in 0.5 ng/ml IGF-1 compared to in
serum-free medium alone, which was significant in 1 ng/ml
IGF-1 and was almost complete in the presence of 2 ng/ml
IGF-1 and above. IGF-1 was less potent in EFM-19 than in
MCF-7 but in both cells lines the protective effect of IGF-1
was maximal at a concentration of 15 ng/ml which indicates
that the protective effect of IGF-1 in oestrogen-responsive
breast cancer cells is mediated by the type I IGF receptor.
The concentrations of IGF-1 at which significant prevention
of anoikis was detected coincided with the concentrations
that stimulated Akt and Bad phosphorylation (Fig. 4).
Confirmation of the importance of the type I IGF receptor
in the IGF-1 protection was sought with siRNA knockdown.
Expression of the type I IGF receptor by MCF-7 cells was
reduced to undetectable levels after transfection with an
siRNA oligonucleotide directed against the type I IGF recep-
tor (Fig. 8B). PARP cleavage in cells cultured in poly-
HEMA-coated wells to induce anoikis was inhibited by IGF-
1 in untransfected cells and in cells transfected with scram-
bled oligonucleotide but not in cells in which expression of
the type I IGF receptor had been knocked down. The con-
centration dependence of the IGF-1 anoikis protection, and
the inability of IGF-1 to prevent anoikis in cells without type
I IGF receptor expression, confirm that the protective effect
of IGF-1 against anoikis is transmitted by the type I IGF re-
ceptor in these oestrogen-responsive breast cancer cells.
The importance of the type I IGF receptor was corrob-
orated by pharmacological inhibition with the inhibitory
antibody, figitumumab. Expression of the type I IGF re-
ceptor was barely detectable after incubation with the
anti-receptor antibody (Fig. 8C). Incubation of cells with
figitumumab reduced significantly the ability of IGF-1 to
protect cells from anoikis (Fig. 8C).
To investigate the generality of the importance of the
type I IGF receptor and signalling through the IGF trans-
duction pathway in the anoikis resistance of oestrogen-
responsive breast cancer cells, unattached cells were incu-
bated in the presence of figitumumab in serum-containing
medium. Incubation with figitumumab reduced the
amount of the type I IGF receptor and the activation of
Akt by phosphorylation of Ser473, which indicates that
the type I IGF receptor and the IGF signal transduction
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Fig. 8 Importance of the type I IGF receptor in IGF protection from anoikis. Cells were trypsinised, resuspended in serum-free medium
alone or with the indicated concentrations of IGF-1 (a) or in the presence of IgG2 (−figit.) or figitumumab (+figit.) (c) or in serum-containing medium
in the absence or presence of figitumumab (d) and then placed in 35-mm-diameter poly-HEMA-coated wells and cultured for 24 h
(MCF-7 and ZR-75) or 5 h (EFM-19). MCF-7 cells were left untransfected or transfected with a scrambled non-silencing siRNA duplex
oligonucleotide sequence or an siRNA against type I IGF receptor mRNA and incubated in maintenance medium for 48 h. Cells were
trypsinised, resuspended in serum-free medium alone or with 10 ng/ml IGF-1, placed in 35-mm-diameter poly-HEMA-coated wells and
cultured for 24 h (b). Cells were lysed and aliquots of 10 μg of protein analysed by western transfer for cleaved PARP, type I IGF
receptor, phosphorylated Akt, total Akt and GAPDH as described above. Asterisks show PARP cleavage that is statistically significantly
less in the presence of IGF-1 than in its absence (a) or significantly more in the presence of figitumumab than in its absence (c and d)
(ANOVA, p < 0.01)
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Fig. 9 Association of type I IGF receptor expression with distant metastasis-free survival in breast cancer patients. The association between type I
IGF receptor gene (IGF-IR) expression and time to relapse with distant metastasis was analysed. Kaplan and Meier survival curves are shown for all
patients (a), patients with oestrogen receptor-positive tumours (b), patients with oestrogen receptor-positive tumours and involved lymph nodes
(c), and patients with oestrogen receptor-positive, grade III tumours (d). The differences between the curves was assessed by log rank test and
the curves were considered to be significantly different if p < 0.05
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way in oestrogen-responsive breast cancer cells (Fig. 8D).
Importantly, incubation of the cells with figitumumab in-
duced significantly anoikis in the presence of serum. These
data demonstrate that abrogation of the IGF-protective effect
by pharmacological inhibition of the type I IGF receptor is
able to circumvent the protective effects of anti-anoikis fac-
tors that are present in serum (Fig. 5B). The effectiveness of
figitumumab indicates that the factors that signal through
the IGF signal transduction pathway have a major role in the
anoikis resistance of oestrogen-responsive breast cancer cells.
The pivotal role of the type I IGF receptor in protection
of oestrogen-responsive breast cancer cells from anoikis,
which could be critical for the ectopic survival of themalignant cells, suggests that receptor expression might fa-
cilitate metastasis. Amongst all patients, there was a trend
towards a longer time to relapse with distant metastasis for
patients with high type I IGF receptor expression (Fig. 9A)
which is consistent with previous studies that have demon-
strated survival benefit of high type I IGF receptor expres-
sion [35, 36]. However, amongst the sub-group of patients
with oestrogen receptor-positive breast cancer, those with
higher type I IGF receptor expression had shorter time to
relapse with distant metastasis than those with lower ex-
pression (log rank; p = 0.032) (Fig. 9B). The difference in
time to relapse between patients with high and low recep-
tor expression was even more significant in the subgroup
of patients with oestrogen receptor-positive tumours and
Luey and May Molecular Cancer  (2016) 15:8 Page 12 of 15lymph node involvement (p = 0.0057), and was most sig-
nificant in patients with oestrogen receptor-positive, grade
3 tumours (p = 0.0035) (Fig. 9C and D).
Discussion
The majority of breast cancer deaths are caused by the
effects of distant metastases in vital organs. Metastatic
malignant cells accrue a plethora of characteristics in
distinct phases: metastasis initiation, progression and
virulence [5]. They must be able to survive without
normal cellular and cell matrix attachments to initiate
metastasis. The development of resistance to anoikis, the
apoptotic process triggered by inappropriate or absence
of cell adhesion is an important facet of this transition.
Improvements in the management and survival of
breast cancer patients and identification of therapeutic
targets will be facilitated by a more profound understand-
ing of metastasis. To this end, we have established a model
of oestrogen-responsive breast cancer cell anoikis. Anoikis
can be mediated through extrinsic, intrinsic or caspase-
independent apoptotic pathways [37, 38]. There have been
limited studies on anoikis in breast cancer. Breast cancer
cells as exemplified by Hs578T, MDA-MB-231, BT-474
and T-47D have been reported to be inherently resistant
to anoikis and it was concluded that this resistance does
not involve the PI3-kinase/Akt or Grb2/Ras/MAP-kinase
pathways [39]. In contrast, our experiments have identi-
fied conditions that allow analysis of breast cancer cell
anoikis resistance and have highlighted the importance
of the intrinsic apoptotic pathway.
Several signal transduction pathways implicated in anoi-
kis emanate from the focal adhesion complex in response
to integrin-mediated cell adhesion to the extracellular
matrix. Amongst these, phosphorylated FAK interacts with
Grb2 and PI3-kinase [40–42] to activate the Ras/MAP-kin-
ase and Akt pathways, respectively [41, 43]. Our data em-
phasise the importance of the PI3-kinase/Akt pathway in
oestrogen-responsive breast cancer as the rapid and dra-
matic loss of FAK phosphorylation within 15 minutes of
detachment, followed by PARP cleavage after 1 hour, was
associated with a decrease in phosphorylated Akt but an
increase in phosphorylated MAP-kinases. Consistent with
involvement of the intrinsic pathway, Bad phosphorylation
decreased concomitantly with phosphorylated Akt and cas-
pase 3 was activated. Dephosphorylated Bad forms hetero-
dimers with Bcl-2 and Bcl-XL, thereby preventing them
from interacting with and inhibiting Bax and Bak, which
would otherwise form pores in the mitochondrial mem-
brane to release cytochrome c and trigger cell death [38].
Our data show that breast cancer cell culture medium
contains factors that confer anoikis resistance and that the
major factor is a ligand that signals through the type I IGF
receptor. A protective effect of IGF-1 against anoikis
was demonstrated first in mouse embryonic fibroblastsengineered to overexpress the type I IGF receptor [22]. As
far as we are aware, this is the first demonstration that IGFs
protect breast cancer cells from caspase-dependent anoikis.
Many mechanisms are suggested to explain how malig-
nant cells that detach from primary tumours evade cell
death. These include changes to integrin expression [44],
hypoxia which induces ligand-independent activation of
growth factor receptors and redox-mediated decrease of
pro-apoptotic factors [45], and EMT activation [46]. Our
results demonstrate that oestrogen-responsive breast can-
cer cells avoid anoikis via a prosurvival pathway in which
the type I IGF receptor is activated by IGFs. The type I
IGF receptor is expressed widely on breast cancer cells
and mediates the effects of IGFs on cell migration [13, 47]
and proliferation [11, 12, 48]. IGF-1 activated both the
PI3-kinase/Akt and Grb2/Ras/MAP-kinase pathways but
our experiments with PI3-kinase, Akt and MEK inhibitors
establish that anoikis resistance is conferred preferentially
through the PI3-kinase/Akt pathway.
Although the Grb2/Ras/MAP-kinase pathway is not in-
volved in the anoikic resistance of oestrogen-responsive
breast cancer cells, its inhibition induces significant cell
death which is abrogated almost completely by IGF-1. IGF-
1 overcomes the cell death signal induced by inhibition
of MEK1 and MEK2 without an increase in MAP-
kinase phosphorylation. These results suggest that
inhibition of the Grb2/Ras/MAP-kinase pathway is un-
likely to be effective in the treatment of oestrogen-
responsive breast cancer unless treatment is combined
with inhibition of IGF signal transduction.
IGFs may signal through the type I IGF receptor, through
isoform A and, to a lesser extent, through isoform B of the
insulin receptor [9, 34, 49]. The receptor involved is of
clinical importance because drugs such as figitumumab,
cixutumumab, ganitumab and dalotuzumab are directed
specifically against the type I IGF receptor [16–19] whereas
BMS-754807 and linisitinib inhibit both the type I IGF and
insulin receptors [20, 21]. Our data indicate that signalling
through the type I IGF receptor is dominant in oestrogen-
responsive breast cancer.
Conclusions
We have established a reliable model of caspase-dependent
anoikis for oestrogen-responsive breast cancer cells. We
demonstrate the importance of the intrinsic pathway in
anoikis and that IGF-1 can reinstate anoikis resistance of
unattached oestrogen-responsive breast cancer cells
cultured in serum-free medium. IGF-1 activated both the
PI3-kinase/Akt and Grb2/Ras/MAP-kinase pathways but
our experiments with PI3-kinase, Akt and MEK inhibitors
show that anoikis resistance is conferred through the PI3-
kinase/Akt pathway. Although ERK1 and ERK2 are not
important in IGF-dependent anoikis-resistance, IGF-1 is
able to circumvent apoptosis induced by inhibition of
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phosphorylation. The IGF-1 signal is transduced via the
type I IGF receptor and incubation with type I IGF receptor
specific antibody, figitumumab, induces anoikis of cells
grown in serum. This is the first demonstration of the im-
portance of IGFs and the type I IGF receptor in the resist-
ance of oestrogen-responsive breast cancer cells to caspase-
dependent anoikis. The importance of the type I IGF recep-
tor is supported by the association of higher receptor ex-
pression with earlier relapse with distant metastases in
oestrogen receptor-positive tumours, especially those of
women with more aggressive disease as assessed either by
presence of involved lymph nodes or high histological
tumour grade. Successful targeting of the type I IGF recep-
tor would abrogate effectively the IGF signal for cell survival.
Collectively, our results support the concept that effective
combinations of targeted drugs should include abrogation of
the activity of the IGF signal transduction pathway.
Methods
Cell culture
Breast cancer cell lines: MCF-7, T-47D, ZR-75 and EFM-19
were obtained from the American Type Culture Collection
(Manassas, VA) or DMCSZ and cultured routinely in
Dulbecco’s modified Eagle’s medium (DMEM) (Sigma,
Poole, United Kingdom), supplemented with 10 % foetal
calf serum (FCS) and 1 μgml−1 insulin in a humidified incu-
bator at 37 °C with 5 % CO2.
Anoikis assay
The non-ionic acid poly(2-hydroxyethyl methacrylate) (poly-
HEMA; SIGMA) which inhibits matrix deposition and cell
attachment [26] was dissolved in 99 % ethanol at 10 mgml−1.
Twelve-well tissue culture plates were coated twice with
0.5 ml poly-HEMA solution, allowed to dry, washed with
phosphate-buffered saline (PBS) and stored at 4 °C.
Cells were trypsinised, 40 × 104 cells added to 35-mm-
diameter poly-HEMA-coated wells and cultured in
maintenance medium or in serum-free, phenol red-free
DMEM in the absence or presence of IGF-1 for different
lengths of time. Cells were recovered, centrifuged, and
lysed for protein analysis. Cells were incubated without
and with 20 μM PI3-kinase inhibitor, LY294002, (Sigma),
100 nM Akt inhibitor, GSK 690693, (SYN│thesis med
chem Pty Ltd., Cambridge, United Kingdom) or 6 μM
MEK 1 and MEK2 inhibitor, UO126, (SIgma) for 30 min
prior to addition of IGF-1. The type I IGF receptor in-
hibitory antibody figitumumab [16] was from Pfizer Inc.
(Tadworth, United Kingdom). Cells were centrifuged,
and lysed for protein analysis.
Activation of caspase 3 was measured with the BD Phar-
mingen FITC-conjugated active caspase 3 apoptosis kit I
(BD Biosciences, Oxford, United Kingdom). Cells were
added to 16-mm-diameter poly-HEMA-coated wells at40 × 104 cells/well in 2 ml of serum-free medium in the
absence or presence of 50 ng/ml IGF-1 and incubated for
5 h. Cells were recovered, centrifuged, washed in PBS and,
resuspended in 0.2 ml Cytofix/Cytoperm solution and in-
cubated on ice for 20 min. Cells were then washed twice
with 0.2 ml Perm/Wash solution, resuspended in 100 μl
Perm/Wash solution with 8 μl and FITC-conjugated anti-
activated caspase 3 antibody, protected from light and
incubated for 30 min. Cells were rewashed, centrifuged
and resuspended in 400–500 μl Perm/Wash solution.
Fluorescence was measured with a BD FACScan flow
cytometer. Excitation was at 488 nm and emission was
measured at 530 ± 15 nm.
Knockdown of the type I IGF receptor
The sequence of the double-stranded short interfering
RNAs (siRNA) designed to target the type I IGF receptor
mRNA was 5’-CGACUAUCAGCAGCUGAAGTT-3’, and
equivalent non-silencing scrambled sequence was 5’-UUC
UCCGAACGUGUCACGUdTdT-3’ (Sigma). The siRNA
duplex was mixed with RNA iMax (Invitrogen, Paisley,
United Kingdom) in serum-free DMEM and incubated
30 min at room temperature. MCF-7 cells were trypsi-
nised, resuspended in maintenance medium at a density
of 25 × 104 cellsml−1, mixed with the transfection medium
and added to a 25 cm2 flask. Cells were tested in anoikis
assays or lysed for protein analysis, after incubation for
48 h or 96 h, respectively.
IGF-1 stimulated protein phosphorylation
Cells were added to 16-mm-diameter wells at a density of
15 × 104 cells/well for MCF-7 and ZR-75 cells, and 20 × 104
cells/well for EFM-19 cells. Cells were allowed to attach for
24-48 h and withdrawn from stimulatory factors in serum
by culture for 48 h in growth factor-depleted medium,
comprising phenol red-free DMEM and 10 % dextran-
coated, charcoal-treated serum. Medium was changed daily.
Cells were incubated with different concentrations of IGF-1
for 15 min, lysed and analysed by Western transfer [12].Western transfer analysis
Cells were lysed in radioimmunoprecipitate (RIPA) buffer
which comprised 50 mM Tris–HCl pH 7.5, 150 mM NaCl,
1 mM EDTA, 1 % NP-40 (v/v) and 0.25 % sodium deoxy-
cholate (w/v, 1 μgml−1 pepstatin, 1 μgml−1 aprotinin, 1
μgml- 1 leupeptin, 2 mM sodium orthovanadate, 2 mM so-
dium fluoride and 2 mM phenyl methyl sulphonyl fluoride.
Protein concentrations were measured with a bicinchonic
acid assay (Thermo Scientific, Loughborough, United King-
dom). Equal amounts of protein were separated by electro-
phoresis on denaturing 12 % polyacrylamide gels and
transferred to a Westran 0.45 μm nitrocellulose membrane
(VWR, Leicestershire, United Kingdom) [50]. Membranes
Luey and May Molecular Cancer  (2016) 15:8 Page 14 of 15were incubated with specific antibodies against: cleaved
poly-(ADP-ribose) polymerase (PARP) (#9541), type I IGF
receptor (#3027), phosphorylated type I IGF receptor
Tyr1135&1136 and insulin receptor Tyr1150&1151.
(#3024), Akt (#9272), phosphorylated Akt Ser473 (#4060),
FAK (#3285), phosphorylated FAK Tyr397 (#3283), ERK1
and ERK 2 (#9102), phosphorylated ERK 1 and ERK2 Thr
202 or Tyr 204 (#4370), Bad (#9292), phosphorylated Bad
Ser136 (#4366), GSK3β (#9315), phosphorylated GSK3β
Ser9 (#9323) (Cell Signaling Technologies, Hitchin, United
Kingdom), IRS-1 (sc-7200), phosphorylated IRS-1 Tyr632
(sc-17196-R), and GAPDH (sc-25778) (Santa Cruz Biotech-
nology, Heidelberg, Germany). Membranes were incubated
with horseradish peroxidase conjugated secondary anti-
bodies followed by enhanced chemiluminescence with
SuperSignal West Dura Substrate (Thermo Scientific) and
exposure to SuperRX X-ray film (Fujifilm, Bedford, United
Kingdom). The intensity of the protein bands was
quantified by densitometry with Labworks 4.0 software
(UVP Inc., Cambridge, United Kingdom).Statistics
For the western transfer images, a representative example
is shown. Data were normalized and expressed as a per-
centage of the maximum cleaved PARP or activated signal
transduction protein detected. Results are expressed as
means ± S.E.M. Differences between groups were tested
by analysis of variance, paired or unpaired t-test; p < 0.05
was considered statistically significant. Experiments were
replicated at least thrice. The association between type I
IGF receptor expression and time to relapse with distant
metastasis was analysed by the log rank test on data from
The Cancer Genome Atlas.
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